← Leaderboards
Efrat Levy
New York University School Of Medicine
$16,670,052
Attributed
$22,876,307
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.9M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$22,876,307 · 13
By mechanism
R01$8,621,978 · 5
RF1$7,287,601 · 3
P01$6,966,728 · 5
Top collaborators
- Donald A Wilson7 shared
- Ralph A. Nixon5 shared
- Mariko Saito5 shared
- Paul M. Mathews3 shared
- Pasquale D'Acunzo1 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Ralph A. Nixon$26,583,271
- Edward B Ziff$11,684,955
- Vilma Gabbay$24,919,783
- Martin Joseph Sadowski$14,045,716
- George G Holz$7,757,380
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposPathologyCellsS DiseaseNeuronsAffectMolecularFunctional DisorderBrainBaseIn VitroAmyloid Beta-Protein PrecursorEndosomesLinkBehavioralMouse ModelPathway InteractionsPost Gamma-GlobulinsDepositionExtracellular VesiclesAmyloidDown SyndromeMutantTransgenic Organisms
Grant awards (52)
Apolipoprotein E genotype modulates brain mitovesicle production, a component of mitochondrial quality control$2,499,343
RF1 · FY2024 · AG · contact PI
A new perspective on the role of extracellular vesicles in Alzheimer's disease$2,413,601
RF1 · FY2024 · AG · contact PI
Core B: Mouse models Core$461,737
P01 · FY2021 · AG · contact PI
Brain exosomes mediate cocaine-induced addiction$423,068
R01 · FY2021 · DA · contact PI
Preventing early events in Aβ-driven pathology in vivo$404,250
R01 · FY2021 · AG · contact PI
Regulation of extracellular vesicle secretory pathways in Alzheimer's disease$279,393
P01 · FY2021 · AG · contact PI
Core B: Mouse models Core$461,737
P01 · FY2020 · AG · contact PI
Brain exosomes mediate cocaine-induced addiction$431,937
R01 · FY2020 · DA · contact PI
Preventing early events in Aβ-driven pathology in vivo$404,250
R01 · FY2020 · AG · contact PI
Regulation of extracellular vesicle secretory pathways in Alzheimer's disease$279,393
P01 · FY2020 · AG · contact PI
Neuronal Protective Apolipoprotein E2-mediated endocytic and exocytic pathways$249,884
RF1 · FY2020 · AG · contact PI
Core B: Mouse models Core$461,738
P01 · FY2019 · AG · contact PI
Brain exosomes mediate cocaine-induced addiction$440,548
R01 · FY2019 · DA · contact PI
Preventing early events in Aβ-driven pathology in vivo$404,250
R01 · FY2019 · AG · contact PI
Regulation of extracellular vesicle secretory pathways in Alzheimer's disease$279,393
P01 · FY2019 · AG · contact PI
Core B: Mouse models Core$461,738
P01 · FY2018 · AG · contact PI
Brain exosomes mediate cocaine-induced addiction$450,004
R01 · FY2018 · DA · contact PI
Preventing early events in Aβ-driven pathology in vivo$404,250
R01 · FY2018 · AG · contact PI
Regulation of extracellular vesicle secretory pathways in Alzheimer's disease$279,393
P01 · FY2018 · AG · contact PI
Neuronal Protective Apolipoprotein E2-mediated endocytic and exocytic pathways$2,124,773
RF1 · FY2017 · AG · contact PI
Brain exosomes mediate cocaine-induced addiction$465,174
R01 · FY2017 · DA · contact PI
Core B: Mouse models Core$461,736
P01 · FY2017 · AG · contact PI
Preventing early events in Aβ-driven pathology in vivo$397,574
R01 · FY2017 · AG · contact PI
Regulation of extracellular vesicle secretory pathways in Alzheimer's disease$277,490
P01 · FY2017 · AG · contact PI
Modulation of Olfactory Sensory Function by Amyloid-beta$314,183
R01 · FY2015 · AG
TRANSGENIC CORE$219,432
P01 · FY2015 · AG · contact PI
Modulation of Olfactory Sensory Function by Amyloid-beta$323,900
R01 · FY2014 · AG
TRANSGENIC CORE$226,218
P01 · FY2014 · AG · contact PI
Modulation of Olfactory Sensory Function by Amyloid-beta$306,086
R01 · FY2013 · AG
TRANSGENIC CORE$213,777
P01 · FY2013 · AG · contact PI
Modulation of Olfactory Sensory Function by Amyloid-beta$323,900
R01 · FY2012 · AG
TRANSGENIC CORE$226,218
P01 · FY2012 · AG · contact PI
Modulation of Olfactory Sensory Function by Amyloid-beta$323,900
R01 · FY2011 · AG
CYSTATIN C INHIBITOR OF NEURONAL ABNORMALITIES IN AD$287,716
P01 · FY2009 · AG · contact PI
TRANSGENIC CORE$230,728
P01 · FY2009 · AG · contact PI
CYSTATIN C INHIBITOR OF NEURONAL ABNORMALITIES IN AD$259,308
P01 · FY2008 · AG · contact PI
TRANSGENIC CORE$207,945
P01 · FY2008 · AG · contact PI
CYSTATIN C INHIBITOR OF NEURONAL ABNORMALITIES IN AD$277,947
P01 · FY2007 · AG · contact PI
TRANSGENIC CORE$227,236
P01 · FY2007 · AG · contact PI
Animal models for cerebral amyloid angiopathy$301,843
R01 · FY2006 · NS · contact PI
CYSTATIN C INHIBITOR OF NEURONAL ABNORMALITIES IN AD$245,169
P01 · FY2006 · AG · contact PI
TRANSGENIC CORE$200,448
P01 · FY2006 · AG · contact PI
Animal models for cerebral amyloid angiopathy$306,352
R01 · FY2005 · NS
CYSTATIN C INHIBITOR OF NEURONAL ABNORMALITIES IN AD$238,028
P01 · FY2005 · AG
TRANSGENIC CORE$202,810
P01 · FY2005 · AG
Animal models for cerebral amyloid angiopathy$303,704
R01 · FY2004 · NS
Animal models for cerebral amyloid angiopathy$301,158
R01 · FY2003 · NS
BETAAPP MODULATION BY THE ADAPTER PROTEINS FE65 AND X11$289,200
R01 · FY2003 · AG
BETAAPP MODULATION BY THE ADAPTER PROTEINS FE65 AND X11$286,731
R01 · FY2002 · AG
Animal models for cerebral amyloid angiopathy$274,960
R01 · FY2002 · NS
BETAAPP MODULATION BY THE ADAPTER PROTEINS FE65 AND X11$371,250
R01 · FY2001 · AG
BETAAPP MODULATION BY THE ADAPTER PROTEINS FE65 AND X11$369,506
R01 · FY2000 · AG